Biography for Damian Garde
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Boston Scientific has launched a U.S. trial of two next-generation leads for defibrillators and pacemakers, working toward FDA approval after completing the first implant.
With its $13.6 billion acquisition of Life Technologies finally wrapped up, Thermo Fisher posted huge gains in revenue and profit in its first quarter as a combined company, raising the stakes for 2014 as it plans for more growth.
The FDA has handed a warning letter to Teleflex, citing manufacturing issues at an Illinois plant that produces nebulizers, humidifiers and other respiratory technologies.
The Netherlands' EndoStim convinced European regulators that MRI scans won't harm patients using its LES system, an implant designed to to stimulate the esophagus and relieve acid reflux symptoms.
The bearish market that led Lombard Medical to delay its IPO and TriVascular Technologies to price below its range has scuttled a fundraise from diagnostics luminary Foundation Medicine.
Medical device outfit TriVascular Technologies picked up $78 million as it made its Wall Street debut Wednesday, pricing below its expected range amid a prolonged slump for life sciences stocks.
Despite long-running headwinds, St. Jude Medical pulled off an increase in implanted defibrillator revenue in the first quarter, helping the company swing to a small rise in sales.
GE Healthcare has been no stranger to dealmaking over the past year, and the company's CEO said it has no plans to let up.
Covidien is gearing up to launch its Kangaroo feeding tube in the U.S. after picking up FDA clearance for the device, which is outfitted with a camera that provides real-time images to physicians.
Abbott Laboratories has secured the FDA's blessing to launch its latest diabetes diagnostic, a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.